Stockscreener 앱 받기
1.62
1.24%
0.01
Cel-Sci Corp. 주식(CVM)의 최신 뉴스
Cel-Sci (CVM) Outlook: Ends Up by 3.14% at $1.64 for the Current Session; Key Range: the Price Remains Bounded by the Supplied Support and Resistance at the CloseHagopian Line - vinanet.vn
CEL-SCI Company Profile & Introduction - Moomoo
CEL-SCI Q3 Results: Per-share loss narrows 65% YoY to $(0.47) - scanx.trade
Cel-Sci shareholders elect directors and approve compensation plans at annual meeting - Investing.com
CEL SCI director granted 110K options at $1.49 | CVM Insider Trading - Stock Titan
CEL-SCI director granted 110K options at $1.49 | CVM Insider Trading - Stock Titan
CEL-SCI (NYSE: CVM) awards CEO 300,000 options over 3 years - Stock Titan
CEL-SCI (NYSE: CVM) awards Cipriano 80K options vesting over 3 years - Stock Titan
CEL-SCI (CVM) awards CSO Talor Eyal 250,000 stock options - Stock Titan
Form 8K CEL-SCI Corp For: 17 August By Investing.com - Investing.com Nigeria
CEL-SCI (NYSEAMERICAN: CVM) CFO lands new 2036 stock option grant - Stock Titan
CEL-SCI (CVM) Advances Multikine Trial Amid Low Valuation and Gu - GuruFocus
CEL-SCI Reports Fiscal Third Quarter 2026 Results - Yahoo Finance
CVM Stock Sinks In Pre-Market Trading After Announcing Second Equity Raise For Its Cancer Drug In Just Over A Month - Stocktwits
Cel-Sci: Fiscal Q3 Earnings Snapshot - marketscreener.com
CEL-SCI (CVM) faces going concern risk amid $16.6M loss and $6.5M cash - Stock Titan
CEL-SCI Corp (CVM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CEL-SCI Corp (CVM) Stock News Today - tradingkey.com
CEL-SCI publishes study on Multikine cancer treatment biomarkers - Investing.com
CEL-SCI (CVM) Advances Oral Cancer Immunotherapy Amid Challengin - GuruFocus
Before surgery, Multikine cut disease-progression risk 49% in study - Stock Titan
CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study - Yahoo Finance
CEL-SCI study on Multikine in oral cancer accepted for publication - Investing.com
CEL-SCI Corp (CVM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CEL-SCI Corp (CVM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CEL-SCI Corp (CVM) Institutional Confidence - TradingKey
CEL-SCI Corp (CVM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CEL-SCI Corp (CVM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CEL-SCI Corp (CVM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CVM|CEL-SCI Corp|Price:1.180|Chg%:+0.010 - TradingKey
CEL-SCI Corp (CVM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CEL-SCI Corp (CVM) Balance Sheet - TradingKey
TradingKey - TradingKey
CVM|CEL-SCI Corp|Price:1.720|Chg%:+0.105 - TradingKey
Cel-Sci Corporation Q4 2024 Earnings: Narrowed Loss Beats Estimates as Clinical Pipeline AdvancesRevenue Guidance Range - dars.gov.et
$1.155 | Cel-Sci Corporation (CVM) Stock Price Today - Binance
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
CEL-SCI launches confirmatory study for head and neck cancer drug - Investing.com
CEL-SCI (CVM) Initiates Global Study for Multikine in Head and N - GuruFocus
Cancer drug Multikine heads into 212-patient global trial for head and neck tumors - Stock Titan
Why Did CEL-SCI Stock Plunge After Its Latest Offering - Kavout | AI
CVMCel-Sci Corp Latest SEC Filings - Finviz
Form DEF 14A CEL-SCI CORPORATION For: 2 July By Investing.com - Investing.com Nigeria
[ARS] CEL SCI CORP SEC Filing - Stock Titan
Equity plans and pay votes at CEL-SCI (NYSE: CVM) 2026 annual meeting - Stock Titan
Form 4 CEL-SCI Corp For: 1 July By Investing.com - Investing.com UK
CEL SCI CORP (CVM) Chief Scientific Officer receives 2,307-share stock grant - Stock Titan
CEL SCI CORP (CVM) CFO receives 4,125-share stock grant in Form 4 - Stock Titan
CEL-SCI (CVM) CEO Kersten granted 5,192 common shares at $1.04 - Stock Titan
CVM: CEL-SCI Partners with Saudi Amarox for Multikine Launch - GuruFocus
CEL-SCI signs distribution deal with Saudi Amarox for Multikine - Investing.com
CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care - The Joplin Globe
CEL-SCI and Saudi Amarox seal Multikine pact at BIO 2026 - Stock Titan
CVM Q4 2024 Earnings: Narrower-Than-Expected Loss as Cel-Sci Advances PipelineProfitability Analysis - dars.gov.et
CVM stock sinks in pre-market trading after announcing second equity raise for its cancer drug in just over a month - MSN
BRIEF-CEL-SCI Announces Closing Of Offering - Dailyhunt
1.11%
0.05%
자본화:
|
볼륨(24시간):